{"id":"W2023764867","doi":"10.1016/j.clbc.2012.01.001","title":"Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial","year":2012,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service; Genentech; National Institutes of Health; Mayo Clinic","keywords":"Vinorelbine; Capecitabine; Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Cancer; Phases of clinical research; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002179874,0.002048999,0.002667344,0.0004910122,0.0005346924,0.001053892,0.001407625,0.001550277,0.006602717],"category_scores_gemma":[0.001093781,0.000838919,0.00161608,0.0005247126,0.001616283,0.0009531974,0.0004140932,0.003670716,0.001559979],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002078864,"about_ca_system_score_gemma":0.003288195,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005029526,"about_ca_topic_score_gemma":0.01781867,"domain_scores_codex":[0.9993894,0.000334046,0.00001502891,0.0001062054,0.00003946414,0.0001158305],"domain_scores_gemma":[0.9990421,0.000160249,0.0001761362,0.00008839852,0.00005046263,0.0004826135],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9105669,0.02469468,0.002659265,0.0004523495,0.001160706,0.0001471035,0.0002074717,0.00125715,0.01028312,0.0003540797,0.006584622,0.04163254],"study_design_scores_gemma":[0.9113114,0.08018943,0.005210268,0.00002393844,0.0003236982,0.0001060283,0.00003164473,0.0004803054,0.0005885871,0.0001338115,0.001583736,0.00001707515],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875683,0.002982839,0.000556266,0.001479697,0.0002961217,0.002051721,0.00151208,0.0001619126,0.003390973],"genre_scores_gemma":[0.9744966,0.00320364,0.002552482,0.002721783,0.0004490269,0.003408022,0.003753509,0.00009657046,0.009318382],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006602717,"threshold_uncertainty_score":0.02208823,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1016132208689963,"score_gpt":0.4580827344753126,"score_spread":0.3564695136063163,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}